Sales and Marketing
News/ News/ Sales and Marketing
Mallinckrodt tries again with kidney drug terlipressin
Phil Taylor
kidney disease, Mallinckrodt, regulatory, terlipressin
0 Comment
Market Access/ News/ News/ News/ Sales and Marketing
Alnylam grabs FDA approval for its second amyloidosis therapy
Phil Taylor
Alnylam Pharmaceuticals, Amvuttra, ATTR amyloidosis, Ionis Pharmaceuticals, Onpattro, regulatory approval, SOBI, Tegsedi
0 Comment
Market Access/ News/ News/ News/ Sales and Marketing
Lilly’s Olumiant okayed in alopecia, with Pfizer, Concert in hot pursuit
Phil Taylor
alopecia, Concert Pharma, Eli Lilly, Incyte, JAK inhibitor, Olumiant, Pfizer
0 Comment
News/ News/ Sales and Marketing
FTC launches probe into pharmacy benefit management sector
Phil Taylor
CVS Caremark, Drug pricing, Express Scripts, Federal Trade Commission, Humana, MedImpact Healthcare Systems, OptumRx, pharmacy benefit manager, Prime Therapeutics
0 Comment
Sales and Marketing/ Views & Analysis/ Views and analysis
Simple ways to support a presenter and benefit from their talk
Oliver Stohlmann
communication, Corporate Survival Hacks, work environment
0 Comment
Oncology/ Sales and Marketing/ Views & Analysis/ Views & Analysis/ Views and analysis
Redefining the approach to cancer care – a mission to improve patient outcomes
mike.hammerton@pharmaphorum.com
breast cancer, cancer care, company profile, Exact Sciences, her2
0 Comment
Digital/ News/ News/ News/ Sales and Marketing
Eversana aims athletes’ mental coaching at pharma sales reps
News/ News/ Sales and Marketing
Pfizer will exit GSK consumer health JV after spinout
Phil Taylor
consumer health, Financial, GlaxoSmithKline, Haleon, M&A, Pfizer
0 Comment